A person wearing a shirt is writing on a piece of paper at the desk

PKRxiv

(pronounced ‘PK Archive’) is a managed open access, collaborative data sharing and visualisation platform for anonymised, individual-level pharmacokinetic (PK) data and associated covariates.


What is PKRxiv?

Many funders of biomedical research now require that data from funded research should be made openly accessible in data repositories along with the publication of primary outcomes. We are developing PKRxiv as a purpose-built platform with functionalities specifically designed to facilitate reuse of PK data from published studies by making them findable, accessible, interoperable and reusable.

As well as enabling collaborative data sharing, PKRxiv includes the PKRxiv Explore, customisable data exploration and visualisation tool that allows users to interact with the data prior to requesting them.

 

What are the benefits & ambition of PKRxiv? 

  • Access to globally representative granular data
  • To extend the impact of data beyond its original study
  • Promoting innovation and reduce redundancies
  • To develop a Gold-standard data resource for robust PK model qualification
  • Opportunities for published data harmonisation, pooling and meta-analysis
  • Creating a bespoke platform for pharmacologists to satisfy requirements for data sharing.

Where can I use it?

You can use the PKRxiv Explorer data visualisation tool here to see how it works and what data are available in the prototype.

You can find out more information about PKRxiv here, where you can explore its other functionalities and provide feedback to enhance ongoing development.

 

PKRxiv is being developed by the Perinatal Pharmacology Group based at the University of Liverpool's Centre of Excellence for Long-acting Therapeutics and is funded by Wellcome.

 

 The CELT logo is a celtic knot that forms a cross shape with the word CELT to the right of it.The Wellcome Trust logo is a letter W with the word Wellcome underneath

Back to: Centre of Excellence for Long-acting Therapeutics